Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.40 +0.06%
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +5.9%
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.68, $0.34 better than the analyst estimate of $0.34. Revenue for the quarter came in at $141.4 million versus the consensus estimate of $131.54 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $557.2 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Axis Capital Limited Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Reduce (3)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
